You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Dose Selection

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

IVF Trial in Mumbai (OPTIVF dosage, traditional drug treament)

Recruiting
  • IVF
  • OPTIVF dosage
  • traditional drug treament
  • Mumbai, Maharashtra, India
    Indira IVF
Mar 30, 2023

COVID-19 Trial in Taipei (CX-4945)

Active, not recruiting
  • COVID-19
  • Taipei, Taiwan
    Taipei Medical University Hospital
Apr 16, 2023

CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Suzhou (ThisCART19A with Dose Level 1, ThisCART19A with Dose Level

Recruiting
  • CAR
  • +2 more
  • ThisCART19A with Dose Level 1
  • ThisCART19A with Dose Level 2
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jan 18, 2023

Graft Failure Trial in Australia, Canada, Israel (Emapalumab)

Terminated
  • Graft Failure
  • Melbourne, Australia
  • +4 more
Jul 25, 2022

Small Cell Lung Carcinoma, Neuroendocrine Tumors Trial (BI 764532)

Not yet recruiting
  • Small Cell Lung Carcinoma
  • Neuroendocrine Neoplasms
  • BI 764532
  • (no location specified)
May 22, 2023

COVID-19 Trial (GLB-COV2-043, BNT162b2/COMIRNATY®)

Not yet recruiting
  • COVID-19
  • (no location specified)
Oct 31, 2022

HIV-1-infection Trial in Moscow, Saint-Petersburg (VM-1500A-LAI, ELPIDA®)

Completed
  • HIV-1-infection
  • Moscow, Russian Federation
  • +1 more
Jan 10, 2022

Parkinson Disease, Sleep Disorder, Fatigue Trial in United States (SunRay Light Boxes)

Active, not recruiting
  • Parkinson Disease
  • +2 more
  • SunRay Light Boxes
  • Birmingham, Alabama
  • +24 more
Dec 13, 2022

AL Amyloidosis Trial in Palo Alto, Detroit, Cleveland (CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD),

Active, not recruiting
  • AL Amyloidosis
  • Palo Alto, California
  • +2 more
Dec 6, 2022

Open Angle Glaucoma, Ocular Hypertension Trial in Newport Beach (NCX 470 0.065%, NCX 470 0.1%, Latanoprost 0.005%)

Completed
  • Open Angle Glaucoma
  • Ocular Hypertension
  • NCX 470 0.065% (initial phase of trial)
  • +4 more
  • Newport Beach, California
    Eye Research Foundation
Oct 20, 2022

A New Protocol for Continuous Vancomycin Infusion Dosing.

Completed
  • Sepsis
  • Vancomycin Treatment
  • Plasma vancoymcin measurements
  • Stockholm, Sweden
    Karolinska University Hospital Solna
Nov 22, 2021

Atopic Dermatitis Trial in Hamburg, Magdeburg, Wuppertal (si-544, Placebo)

Recruiting
  • Atopic Dermatitis
  • Hamburg, Germany
  • +3 more
Sep 27, 2022

Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma Trial in Lausanne (FLASH RT, Conventional RT)

Not yet recruiting
  • Basal Cell Carcinoma
  • Cutaneous Squamous Cell Carcinoma
  • FLASH RT
  • Conventional RT
  • Lausanne, Vaud, Switzerland
    Centre Hospitalier Universitaire Vaudois (CHUV)
Feb 13, 2023

B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Cyclophosphamide injection
  • +2 more
  • Charleston, South Carolina
    Hollings Cancer Center at Medical University of South Carolina
Jan 18, 2023

Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis Trial in Cape Town, Mbeya, Mwanza (BTZ-043, Bedaquiline,

Not yet recruiting
  • Tuberculosis, Pulmonary
  • Other Specified Pulmonary Tuberculosis
  • Cape Town, South Africa
  • +3 more
Jun 22, 2023

Stroke Trial in Shanghai (Low dose tenecteplase, High dose tenecteplase)

Completed
  • Stroke
  • Low dose tenecteplase
  • High dose tenecteplase
  • Shanghai, Shanghai, China
    Huashan Hospital
Mar 30, 2022

Covid19, Vaccine Preventable Disease Trial in Moscow (Gam-COVID-vac M, Placebo)

Recruiting
  • Covid19
  • Vaccine Preventable Disease
  • Gam-COVID-vac M
  • Placebo
  • Moscow, Russian Federation
  • +1 more
Sep 8, 2021

Healthy Trial in Nottingham (Ofev®, Nintedanib formulation 1, Nintedanib formulation 2)

Recruiting
  • Healthy
  • Nottingham, United Kingdom
    Quotient Sciences
Aug 9, 2022

Success of Inhibitor Elimination Using Individualized

Recruiting
  • Haemophilia A
    • Mörfelden-Walldorf, Germany
      Haemophilia centre Rhine Main (HZRM)
    Aug 31, 2021

    Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed

    Recruiting
    • Relapsed Non Hodgkin Lymphoma
    • +2 more
    • autologous CD19-directed chimeric antigen receptor (CAR) T-cells
    • Calgary, Alberta, Canada
    • +5 more
    Jul 18, 2022

    B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent Trial in Maywood (Fludarabine,

    Active, not recruiting
    • B-Cell Acute Lymphoblastic Leukemia, Adult
    • +2 more
    • Maywood, Illinois
      Loyola University
    Aug 11, 2022

    Shock, Septic Trial in Worldwide (nangibotide low dose, nangibotide high dose, )

    Active, not recruiting
    • Shock, Septic
    • nangibotide low dose
    • +2 more
    • Bruxelles, Belgium
    • +42 more
    Sep 19, 2022

    Healthy Trial in Nottingham (BI 685509 oral formulation prototypes, BI 685509 standard oral formulation)

    Completed
    • Healthy
    • R1: Reference Product X
    • +12 more
    • Nottingham, United Kingdom
      Quotient Sciences
    Dec 7, 2022

    Seasonal Allergic Rhinitis Trial in Neptune (Placebo (0.5ml), Placebo (1.0ml), Grass MATA MPL (0.5ml) 5100SU)

    Completed
    • Seasonal Allergic Rhinitis
    • Placebo (0.5ml)
    • +5 more
    • Neptune, New Jersey
      Inflamax Research Inc.
    Jan 28, 2021

    MERS (Middle East Respiratory Syndrome), MERS Trial in Sankt-Peterburg (BVRS-GamVac, )

    Recruiting
    • MERS (Middle East Respiratory Syndrome)
    • MERS
    • BVRS-GamVac
    • placebo
    • Sankt-Peterburg, Russian Federation
      Research Institute of Influenza
    Jan 13, 2021